new glp-1 drug retatrutide Demand for Unapproved Weight-Loss Surges on Social Media This is the worst the
Description
PubMed, Geraedts, Maartje C

Retatrutide, a novel triple receptor agonist targeting glucagon-like peptide-1 (GLP-1), Glucose-Dependent Insulinotropic Polypeptide (GIP), and glucagon receptors, represents a groundbreaking advancement in obesity and T2DM pharmacotherapy

doi: 10.1002/jcp.29204 87 BasalayMVDavidsonSMYellonDM

7 (April)

There are a myriad of medical benefits derived from these medications, including improvements in chronic medical conditions such as hypertension, hyperlipidemia, and sleep apnea, says Lauren Turchin-Orent, MD